linjc16/ctgov huggingface dataset:
The Effect of Bracing on Sagittal Balance in Scoliosis

Study Overview
=================
Brief Summary
-----------------
The goal of the study is to analyze the influence of bracing on sagittal balance in scoliosis. In special we want to observe if there is a difference between two types of TLSO-brace, namely boston and cheneau. Retrospective analyses of Full Spine X-rays of patients who underwent bracing-therapy in the context of scoliosis. Different spinopelvic parameters will be analyzed: pelvic incidence, pelvic tilt, sacral slope, lumbar lordosis, spinopelvic angle, spinosacral angle, thoracal kyphosis. Four different X-rays will be reviewed for these parameters: Profile before bracing therapy Profile after initiation of bracing therapy Profile immediately after termination of bracing therapy Profile more than 3 months after termination of brace It concerns patients with idiopathic scoliosis (exclusion of congenital scoliosis, neuromuscular scoliosis and associated spondylolisthesis). Goal of the study is to check if treatment with TLSO-brace has a delordosing effect on sagittal balance (decrease of lumbar lordosis). The zero-hypothesis: TLSO causes no decrease in lumbar lordosis. Secondary goal is to compare the effect of the BOSTON TSLO-brace and otherwise the CHENEAU TLSO-brace on spinopelvic parameters and lumbar lordosis in special.

Official Title
-----------------
The Effect of Bracing on Sagittal Balance in Scoliosis, Are we Doing the Right Thing?

Conditions
-----------------
Idiopathic Scoliosis

Intervention / Treatment
-----------------
* Device: Boston
* Device: Cheneau


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: late onset idiopathic scoliosis non-operative indication Exclusion Criteria: early onset idiopathic scoliosis neuromuscular scoliosis congenital scoliosis associated spondylolisthesis operative indication

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Cheneau brace | Device: Cheneau<br> <br> |
| Group 2<br>Boston brace | Device: Boston<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delordosing effect of TLSO brace |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between Boston and Cheneau brace concerning delordosing effect |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bracing, sagittal balance
VIBE-assisted DEB Registry

Study Overview
=================
Brief Summary
-----------------
VIBER aims at assessing angiographic outcome of drug-eluting balloon angioplasty assisted by the Vascular Imaging Balloon Catheter (VIBE, Volcano, San Diego, CA) device, which integrates a predilation catheter with electronic intravascular ultrasound capabilities.

Official Title
-----------------
Vascular Imaging Balloon Catheter-assisted Drug-eluting Balloon Angioplasty Prospective Registry

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: VIBE + drug-eluting balloon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years De novo native vessel lesion RVD 2.5 - 4 mm Limited compliance with >3 month DAPT Exclusion Criteria: LMCA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VIBE-DEB<br> | Device: VIBE + drug-eluting balloon<br>* VIBE before and after durg-eluting balloon angioplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Binary restenosis | Number of patients with a diameter stenosis >50% assessed by quantitative coronary angiography | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procedural success | Number of patients with both post-procedure diameter stenosis <20% assessed by quantitative coronary angiography and TIMI 3 flow | 1 day | 
| Major adverse cardiac events | Number of patients with one of the following events: cardiac death, non-fatal myocardial infarction, target lesion revascularization | 6 months |
Risk Factors,PREvention and OutComes for CI-AKI in PatientS undErgoing PCI at Intensive Care Unit(PRECISE-ICU)

Study Overview
=================
Brief Summary
-----------------
A retrospective, observational study included all consecutively critically ill patients undergoing percutaneous coronary intervention(PCI) at intensive care unit (ICU) in Fujian Provincial Hospital from January 1st 2012 to December 31st 2018. The aim was to determine the incidence,risk factors,prophylactic strategy and outcomes of CI-AKI in critically ill patients undergoing PCI.

Official Title
-----------------
Risk Factors,PREvention and outComes for Contrast-Induced Acute Kidney Injury in patientS undErgoing Percutaneous Coronary Intervention at Intensive Care Unit：a Single-center Cohort Study(PRECISE-ICU)

Conditions
-----------------
CIN

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients undergoing PCI at ICU Exclusion Criteria: pregnancy lactation end-stage renal disease (eGFR <15 mL/min/1.73 m2) long-term dialysis treatment intravascular administration of contrast medium within the last 7 or 3 days postoperatively

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CI-AKI | an absolute SCr increase ≥0.3 mg/dL or a relative increase in SCr ≥50% within 48 hours of contrast medium exposure | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in-hospital adverse events | congestive heart failure [CHF], bleeding, stroke, reinfarction, stent thrombosis, required renal replacement therapy, length of hospital stay, hospital costs, and mortality | 1 year |
Cost-effectiveness of FDG-PET

Study Overview
=================
Brief Summary
-----------------
Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Detailed Description
-----------------
To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

Official Title
-----------------
Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Conditions
-----------------
Oncologic Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer Exclusion Criteria: Other malignancy Uncontrolled Diabetes Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| oncologic patients<br>initial staging | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FDG-PET, cancer, staging, Evaluate the cost impact in the evaluation of oncologic patients.
Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst

Study Overview
=================
Brief Summary
-----------------
The management of pilonidal cysts is a skin excision and under deep skin. Scarring requires regular dressings (daily for 15 days and then every 48 hours) until complete healing. This healing is obtained on average in 68 days. Some patients have difficulties in healing with a final healing achieved on average in 95 days. Some teams use honey to promote wound cavitary wounds (wound infection, pressure ulcers, varicose wound). The acceleration of wound healing is due to antibacterial properties and hyperosmolarity to reduce secretions. ) The use of honey in pilonidal cysts is not evaluated and may accelerate healing.

Official Title
-----------------
Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst

Conditions
-----------------
Pilonidal Cysts

Intervention / Treatment
-----------------
* Device: Melectis G


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cavity Wound to 6 weeks of a pilonidal cyst excision Bloodless wound Pilonidal cyst not recurred Age : 18 years and older Signature of informed consent In the capacity to understand the study Exclusion Criteria: Bleeding wound Refused to participate in Protocol Patient immunocompromised Recurrent pilonidal cyst Patients on long-term corticosteroid Patient deprived of liberty, under guardianship Patient unable to understand the study Allergy or hypersensitivity to honey Allergy Or hypersensitivity to hyaluronic acid Allergy or hypersensitivity to guar gum Allergy or hypersensitivity to pectin Known allergy to propolis (potentially present in honey) Sensitivity to zinc oxide Sensitivity known dressings used in this trial or any component Diabetes Non-insulin or insulin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: standard dressings<br>In general, the dressings made are either of the type : Algosteril® (round or flat wick) + Mepilex® border or AquacelTM ExtraTM + AquacelTM Foam | |
| Experimental: standard dressings with sterile honey<br>Melectis G | Device: Melectis G<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing Time |  | from randomization to 180 days maximum | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
honey, pilonidal cysts, Cavity wound, long healing
Treatment of Wounds Utilizing Light

Study Overview
=================
Brief Summary
-----------------
The Qray device is emitting broad light energy that is intended for diabetic ulcer healing. The study is double blinded.

Conditions
-----------------
Diabetic Ulcer

Intervention / Treatment
-----------------
* Other: Qray light therapy device
* Device: Qray light therapy device-Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has 8 weeks venus leg ulcer. The ulcer was not better on prior treatment of various medical clinics. The patient has diabetic ulcer grade 1 or 2 Exclusion Criteria: Patient has severe infection. Patient is taking antibiotic Patient has ankle brachial index less than 0.7 Patient is schedule to undergone revascularization surgery 10 weeks before the study Patient has photosensitive disease Patient has cancer Creatinine level is more than 2 mg% Patient is taking immunosuppressive medication. Pregnant women Dialysis patient Anaemic patients(less than 9 gr) Patient has Albumin level less than 3 mg%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: 1<br>The device is emitting a sham light | Device: Qray light therapy device-Sham<br>* non curative light- the device emits the same broad light, but with very low intensity<br>|
| Experimental: 2<br>The device is emitting curative light | Other: Qray light therapy device<br>* The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The wound healing process |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ulcer wound diabetes
Transcervical Foley Catheter With or Without Oxytocin for Induction of Labor

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study is to evaluate the possible benefit of concurrent IV Oxytocin infusion with trans cervical Foley catheter for pre-induction cervical ripening.

Detailed Description
-----------------
Induction of labor in term pregnancy may be challenging, especially in patients with unfavorable cervical conditions. Numerous trails have presented evidence of the efficacy of the trans cervical Foley catheter for pre-induction cervical ripening.The purpose of the present study is to evaluate the possible benefit of concurrent IV Oxytocin infusion with trans cervical Foley catheter for pre-induction cervical ripening.

Official Title
-----------------
Transcervical Foley Catheter With or Without IV Oxytocin Infusion for Induction of Labor: a Randomized Controlled Trial

Conditions
-----------------
Pregnancy, Induction of Labor

Intervention / Treatment
-----------------
* Drug: Oxytocin IV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term pregnancy Medical indication for labor induction by transcervical Foley catheter Exclusion Criteria: Preterm pregnancy Contraindication for induction of labor by transcervical Foley catheter or by IV Oxytocin: Uterine scar Multiple pregnancy PROM Grand-multiparity Placenta previa or marginal placenta Spontaneous uterine contractions (more than 3 in 10 minutes) Vaginal bleeding Nonreassuring fetal heart rate

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Transcervical Foley catheter with IV Oxytocin | Drug: Oxytocin IV<br>* 5 miu/1000ml Glu/Saline<br>* Other names: Pitocin;|
| No Intervention: 2<br>Transcervical Foley catheter only | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The period of time needed for ripening the uterine cervix by Transcervical Foley catheter with or without IV Oxytocin infusion. |  | year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Induction of Labor, Low Bishop Score, Transcervical Foley Catheter., IV Oxytocin
Evaluation of High-Density Lipoprotein in Obesity Study

Study Overview
=================
Brief Summary
-----------------
Obesity is associated with an impaired functioning HDL (good cholesterol) resulting in an acceleration in the development of atherosclerosis. This study will evaluate HDL functionality in patients with BMI (Body Mass Index) 20 - 25 and BMI >30

Detailed Description
-----------------
This study will determine if the protective function of high-density lipoprotein (HDL) is impaired in obese patients and will help to enhance cardiovascular risk prediction. Carotid intima-media thickness (cIMT) will be captured as a means of assessing early vascular changes associated with low HDL levels in obesity. A novel measurement for clinical correlation has also been introduced called carotid extra-medial thickness (cEMT) which will be compared to cIMT in this obese population.

Official Title
-----------------
Evaluation of High-Density Lipoprotein in Obesity Study

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group 1: Age 20-80 English speaking BMI 20-25 kg/m2 Group 2: Age 20-80 English speaking BMI > 30 kg/m2 TG > 150 and HDL > 50 (females) >40 (Males) Group 3: Age 20-80 English speaking BMI > 30 kg/m2 TG > 150 and HDL < 50 (females) < 40 (males) Exclusion Criteria: Self-reported history of: Diabetes mellitus Any previous lipid therapy within the last three months Macrovascular events including TIA, stroke, myocardial infarction, heart failure, claudication, or known peripheral vascular disease Current pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>BMI 20-25 kg/m2 | |
| 2<br>BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males) | |
| 3<br>BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine whether the functional activity of HDL is impaired in the setting of obesity |  | Within 2 weeks of enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine whether HDL is more susceptible to oxidative modification ex-vivo in obese patients by mass spectrometry |  | Within 2 weeks of enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, HDL, HDL functionality
Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study

Study Overview
=================
Brief Summary
-----------------
Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers

Official Title
-----------------
Maternal And Neonatal Outcome of Pregnant Patients With COVID-19

Conditions
-----------------
Covid19, Maternal-Fetal Relations

Intervention / Treatment
-----------------
* Other: newborns from covid 19 positive mothers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: from covid 19 positive mothers newborn mothers had not other condition or illness Exclusion Criteria: from covid 19 negative mothers childs

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 15 Minutes

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of apgar status of newborns from covid 19 positive mothers | The Apgar score is looked after at 1 and 5 minutes after birth, if the baby's Apgar score is lower than 7, it is repeated every 5 minutes until 20 minutes. Parameters examined in Apgar score Muscle tone, Heart rate, Reflexes, Skin color, Respiration. In the Apgar score, the baby is evaluated and scores are collected. 7 - 10: The baby is normal. 4 - 6: They usually recover with respiratory support. 0 - 3: Urgent intervention and resuscitation is needed. The low Apgar score in the 1st minute usually returns to normal in the 5th minute with support. Despite the intervention, the Apgar scores of 5 and less at 5 and 10 minutes are associated with an increased risk of mortality and cerebral palsy. | 2 months |
Analysis of Human Tear Proteins in Children

Study Overview
=================
Brief Summary
-----------------
The significance of our study is in the importance of understanding the quality and quantity of proteins in the human tear film, and any unique aspects of tears in children. This pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.

Official Title
-----------------
Analysis of Human Tear Proteins in Children: A Pilot Study to Describe the Tear Film Proteome of Pediatric Patients Undergoing Ophthalmic Examination.

Conditions
-----------------
Eye Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Less than 18 years of age A parent or legal guardian provide written informed consent to participate Able to cooperate with tear sample collection, or a previously planned sedation for other medical purposes Exclusion Criteria: Age greater than or equal to 18 years Patients' parents or legal guardians who refuse to sign study consent

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proteome of Human Tears |  | Single Exam | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tear protein